Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience
Grace C Lovett, Tin Nguyen, David M Iser, Jacinta A Holmes, Robert Chen, Barbara Demediuk, Gideon Shaw, Sally J Bell, Paul V Desmond, Alexander J Thompson, Department of Gastroenterology, St Vincent’s Hospital Melbourne, Fitzroy 3065, Australia
Grace C Lovett, Tin Nguyen, David M Iser, Jacinta A Holmes, Robert Chen, Barbara Demediuk, Gideon Shaw, Sally J Bell, Paul V Desmond, Alexander J Thompson, Faculty of Medicine, University of Melbourne, Parkville 3010, Australia
Author contributions: Lovett GC data collection, data analysis and manuscript composition; Nguyen T, Iser DM, Chen R, Demediuk B, Shaw G and Bell SJ data collection; Holmes JA data collection and manuscript reviewing; Desmond PV planned study, supervised data collection and analysis and revised manuscript; Thompson AJ planned study, supervised data collection and analysis and revised manuscript.
Institutional review board statement: This study was reviewed and approved by the St Vincent’s Hospital Melbourne Review Board.
Informed consent statement: Informed consent was not required for this study as only a retrospective audit was undertaken. The confidentiality of participant records has been maintained at all times, with patient information remaining deidentified.
Conflict-of-interest statement: Thompson AJ is an advisor/consultant to Gilead Sciences; has received research funding and acted as a speaker for Gilead Sciences; NHMRC fellowship Translational studies into viral hepatitis.
Data sharing statement: No data were created so no data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Alexander J Thompson, MBBS, FRACP, PhD, Department of Gastroenterology, St Vincent’s Hospital Melbourne, Level 4 Daly Wing, 35 Victoria Parade, Fitzroy 3065, Victoria, Australia. alexander.thompson@svha.org.au
Telephone: +61-3-92883581
Received: May 8, 2016
Peer-review started: May 10, 2016
First decision: June 18, 2016
Revised: July 29, 2016
Accepted: September 21, 2016
Article in press: September 22, 2016
Published online: January 8, 2017
Peer-review started: May 10, 2016
First decision: June 18, 2016
Revised: July 29, 2016
Accepted: September 21, 2016
Article in press: September 22, 2016
Published online: January 8, 2017
Core Tip
Core tip: Clinical trials have demonstrated that tenofovir is a safe and efficacious treatment for patients with chronic hepatitis B, with high rates of sustained virological suppression. There are limited data evaluating the safety and efficacy of tenofovir in real-world settings. The aim of this study was to evaluate the long-term treatment outcomes of tenofovir therapy in patients in an Australian tertiary care setting. We performed a retrospective analysis of treatment outcomes among treatment-naïve and treatment-experienced patients.